NASDAQ:OBLNObalon Therapeutics Stock Price, Forecast & News

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OBLN shares have decreased by 32.7% and is now trading at $0.70. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Obalon Therapeutics.

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Obalon Therapeutics.

Obalon Therapeutics Inc (NASDAQ:OBLN) posted its earnings results on Friday, June, 19th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.17. The company had revenue of $0.78 million for the quarter. Obalon Therapeutics had a negative net margin of 903.19% and a negative return on equity of 149.15%. View Obalon Therapeutics' earnings history.

Shares of Obalon Therapeutics reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

2 brokers have issued 12 month price targets for Obalon Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Obalon Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,328.6% from the stock's current price. View analysts' price targets for Obalon Therapeutics.

News headlines about OBLN stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Obalon Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Obalon Therapeutics.

Some companies that are related to Obalon Therapeutics include Dynatronics (DYNT), Lianluo Smart (LLIT), Avinger (AVGR), PlusTherapeuticsInc . (PSTV), Hypertension Diagnostics (HDII), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP), Invivo Therapeutics (NVIV), Encision (ECIA), RA Medical Systems (RMED), Endologix (ELGX), Cytocore (MDIT), Neurometrix (NURO), Regenicin (RGIN) and Calmare Therapeutics (CTTC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Opko Health (OPK), Inpixon (INPX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Zynerba Pharmaceuticals (ZYNE), Co-Diagnostics (CODX) and Corbus Pharmaceuticals (CRBP).

(OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $0.70.

Obalon Therapeutics has a market capitalization of $5.41 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe.

The official website for Obalon Therapeutics is www.obalon.com.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]